Literature DB >> 15096076

Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness.

Philip D Harvey1, Michael F Green, Richard S E Keefe, Dawn I Velligan.   

Abstract

BACKGROUND: Truly effective treatments for schizophrenia require much more than clinical efficacy. Symptom improvement is all that is required to demonstrate clinical efficacy. However, for a treatment to be effective in a wide-ranging manner, improvement in various life domains, such as social functioning, independent living, and employment, should also be found. Thus, a much wider range of improvements, not widely produced by previous treatments, is required to take treatment for schizophrenia to a new level of effectiveness. CONSENSUS PROCESS: A teleconference consensus meeting was held with the bylined authors on December 10, 2002, to explore the factors that hinder the most effective treatments for schizophrenia. We argue that a possible unifying factor underlying these apparently disparate domains of effective treatment is cognitive functioning, which is impaired in people with schizophrenia. Treatment of cognitive dysfunction may have a central role in increasing the breadth of effective treatment for schizophrenia.
CONCLUSIONS: Novel antipsychotics and specific cognitive-enhancing medications have preliminarily been shown to have cognitive benefits that might lead to broader effectiveness of treatments, eventually reflected in improvements in the daily lives of patients. These treatments may have their greatest impact when combined with focused psychological interventions. While the research to date does not provide a large number of successes, this area will be one of considerable research interest for the next decade, with developments likely to be very important to clinicians treating patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15096076

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  50 in total

1.  Evaluation of the antipsychotic potential of Panax quinquefolium in ketamine induced experimental psychosis model in mice.

Authors:  Manavi Chatterjee; Seema Singh; Reena Kumari; Anil Kumar Verma; Gautam Palit
Journal:  Neurochem Res       Date:  2011-12-22       Impact factor: 3.996

2.  Low BDNF is associated with cognitive impairment in chronic patients with schizophrenia.

Authors:  Xiang Yang Zhang; Jun Liang; Da Chun Chen; Mei Hong Xiu; Fu De Yang; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2012-01-26       Impact factor: 4.530

Review 3.  TAK-063, a novel PDE10A inhibitor with balanced activation of direct and indirect pathways, provides a unique opportunity for the treatment of schizophrenia.

Authors:  Kazunori Suzuki; Haruhide Kimura
Journal:  CNS Neurosci Ther       Date:  2018-01-09       Impact factor: 5.243

4.  New paradigms for treatment development.

Authors:  Ellen L Stover; Linda Brady; Stephen R Marder
Journal:  Schizophr Bull       Date:  2007-08-02       Impact factor: 9.306

5.  A meta-analysis of cognitive remediation in schizophrenia.

Authors:  Susan R McGurk; Elizabeth W Twamley; David I Sitzer; Gregory J McHugo; Kim T Mueser
Journal:  Am J Psychiatry       Date:  2007-12       Impact factor: 18.112

Review 6.  Performance-based measures of functional skills: usefulness in clinical treatment studies.

Authors:  Philip D Harvey; Dawn I Velligan; Alan S Bellack
Journal:  Schizophr Bull       Date:  2007-05-09       Impact factor: 9.306

Review 7.  Progress in defining optimal treatment outcome in schizophrenia.

Authors:  Gary Remington; George Foussias; Ofer Agid
Journal:  CNS Drugs       Date:  2010-01       Impact factor: 5.749

Review 8.  [Cognitive disorders in schizophrenic patients].

Authors:  H-P Volz; F Reischies; M Riedel
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

9.  Validating measures of real-world outcome: the results of the VALERO expert survey and RAND panel.

Authors:  Feea R Leifker; Thomas L Patterson; Robert K Heaton; Philip D Harvey
Journal:  Schizophr Bull       Date:  2009-06-12       Impact factor: 9.306

10.  Cognitive function, plasma MnSOD activity, and MnSOD Ala-9Val polymorphism in patients with schizophrenia and normal controls.

Authors:  Xiang Y Zhang; Da C Chen; Mei H Xiu; Fu D Yang; Yunlong Tan; Xingguang Luo; Lingjun Zuo; Therese A Kosten; Thomas R Kosten
Journal:  Schizophr Bull       Date:  2013-04-15       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.